{
  "pmcid": "9246793",
  "sha256": "f041d154aadc4e0aadee8ad78c6fa606e82a40ba65574e49e7300a343c8ef456",
  "timestamp_utc": "2025-11-09T16:20:41.272281+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.938461538461539,
    "reading_ease": 36.23153846153849,
    "word_count": 286
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "327 patients with FIGO stage IIIB–IV epithelial ovarian cancer (EOC) who underwent primary or interval CRS were randomized"
      },
      "Participants": {
        "score": 2,
        "evidence": "327 patients with FIGO stage IIIB–IV epithelial ovarian cancer (EOC) who underwent primary or interval CRS"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to either surgery with neutral argon plasma (PlasmaJet) (intervention) or without PlasmaJet (control group)"
      },
      "Objective": {
        "score": 1,
        "evidence": "We investigated whether adjuvant use of a neutral argon plasma device can help increase the complete cytoreduction rate."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the percentage of complete CRS."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "327 patients with FIGO stage IIIB–IV epithelial ovarian cancer (EOC)"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Complete CRS was achieved in 119 patients (75.8%) in the intervention group and 115 patients (67.6%) in the control group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Complete CRS was achieved in 119 patients (75.8%) in the intervention group and 115 patients (67.6%) in the control group (risk difference (RD) 8.2%, 95% confidence interval (CI) –0.021 to 0.181; P = 0.131)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Register NL62035.078.17"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funded by ZonMw"
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}